Background: Data suggest that acute leukemia survivors experience moderate to severe distress that does not significantly decline from diagnosis through survivorship. Objectives: The purpose of this study is to assess acute leukemia survivors’ level and source of self-reported distress from active...

Background: Cytogenetic and molecular features of diseases, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), are increasingly used for diagnostic, prognostic, and treatment decisions in health care. Objectives: This review provides information on the current recommendations for...

Blinatumomab (Blincyto®) has received accelerated approval for treatment of relapsed or refractory acute lymphoblastic leukemia. This article describes the authors’ experience with a multidisciplinary collaboration among nursing, pharmacy, prescribers, and support staff, which has proven to be key...

Background: Acute promyelocytic leukemia (APL), once the most lethal form of adult acute leukemia, has become the most curable. The goal of early and well-managed treatment induction is to reduce the malignant burden of promyelocytes to below the cytologically detectable level. Objectives: Oncology...